All Articles

Painterland Sisters just declared National Skyr Yogurt Day. It's not just a PR stunt; it's a masterclass in modern brand-building and a bet on the future of dairy.

As giants rule the obesity market, small-cap MetaVia pitches a novel dual-agonist and a first-in-class MASH drug. Can its science win the day?

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

As Terry Duffy moves to Executive Chairman, Lynne Fitzpatrick prepares to lead CME. This isn't just succession; it's a calculated move for a new digital era.

As ad tech firm Swivel staffs up with industry veterans, it's not just building a company—it's signaling the ad industry's shift from AI hype to execution.

Verastem Oncology's combo therapy posts impressive early data in a notoriously deadly cancer, revealing a shrewd strategy for tackling drug resistance.

A landmark grant and trial expansion signal a pivotal shift in Parkinson's research, blending genetic targeting, global collaboration, and digital health.

A CAD$40M deal with NorthStar isn't just a contract; it's a strategic pivot, leveraging commercial innovation to gain a sovereign edge in a contested space.

XCharge's new C7 charger boasts record power, but its real test lies in winning public trust. A deep dive into the tech, strategy, and partnerships redefining speed.

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

Hillman Group breaks ground on a massive facility at a dead mall site, centralizing operations in a bold strategic play for efficiency and future growth.

A new mid-year outlook reveals how geopolitical turmoil, the AI boom, and a renewed focus on sovereignty are reshaping investment strategies for a volatile H2 2026.

Glass House Brands follows a new playbook, splitting its business to chase a NYSE listing. Is this the key that unlocks institutional capital for the entire sector?

A new low-risk trial program for hybrid vehicles reveals China's pragmatic strategy to win over markets where pure EVs can't yet compete.

Three of Europe's largest steelmakers warn the EU's climate policy could gut manufacturing. Is this a genuine crisis or a last-ditch bid to delay the inevitable?

For the second year, Kuveyt Türk's academy wins a top global award. We look inside the operational innovation driving its success: an AI-powered talent engine.

Gene therapy firm uniQure plans a 2026 FDA submission for AMT-130, a potential first disease-modifying treatment for Huntington's, on an accelerated track.

New research reveals that custom 3D braces can actively correct spinal curves, not just prevent them from worsening. This paradigm shift in non-surgical care offers new hope.

21 doctors from one practice in a "Top Doctors" Hall of Fame is a headline. But what does it reveal about building trust and innovation in cancer care?

Beyond a simple summer promotion, the renewed Oatly-Nespresso pact reveals a calculated strategy to conquer the future of coffee—a future that is cold, plant-based, and highly profitable.